Breast cancer+2
RecruitingA Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy
A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy
- Disease:Breast cancerBreast cancer metastatic+1
- Substances:Datopotamab Deruxtecan
Spain- Participants:18–64 years · 65+ years
- Substances:Datopotamab Deruxtecan
- Sponsor:AstraZeneca AB


